FDA Grants Priority Review for BridgeBio's BBP-418 NDA, Sets Nov. 27 PDUFA Date
BBIO has more than doubled off its 52-week low of $31.77.
Summary
The FDA has granted Priority Review for BridgeBio's BBP-418 New Drug Application (NDA) for LGMD2I/R9, setting a PDUFA date of November 27, 2026. This follows positive Phase 3 results announced in March and the NDA submission later that month, as well as an 8-K filed today. Priority Review accelerates the FDA's decision timeline and signals the agency's view that BBP-418 could be a significant therapeutic advance. If approved, it would be the first treatment for LGMD2I/R9, a rare genetic muscle disorder. The PDUFA date in November is the next critical milestone.
At the time of this announcement, BBIO was trading at $66.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13B. The 52-week trading range was $31.77 to $84.94. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.